Mele A, Castellano C, Felici A, Cabib S, Caccia S, Oliverio A
Dipartimento di Genetica e Biologia Molecolare, Universit-a di Roma La Sapienza, Italy.
Eur J Pharmacol. 1996 Jul 11;308(1):1-12. doi: 10.1016/0014-2999(96)00266-x.
This study explores the functional interaction between glutamatergic and dopaminergic systems in the modulation of two behavioral responses: locomotor activity and memory consolidation assessed with one-trial inhibitory avoidance. In agreement with previous reports, the NMDA receptor antagonist, (+)-MK-801 ((+)-5-methyl-10,11-dihydro(a,d) cyclohepten-5,10-imine hydrogen maleate), dose dependently enhanced locomotor activity in mice. The selective dopamine D1 receptor antagonist SCH 23390 at doses up to 0.05 mg/kg was unable to affect MK-801-induced locomotor activity, while (-)-sulpiride, but only at high doses (30 mg/kg), and haloperidol (0.05 mg/kg) blocked the MK-801 effect. Hypermotility induced by MK-801 was enhanced by repeated administration of haloperidol (once daily administration for 14 days of 4 mg/kg) or (-)-sulpiride (125 mg/kg), but not SCH 23390 (0.5 mg/kg). Dopamine D1 (SKF 38393)- and D2 (quinpirole)-selective agonists enhanced retention of one-trial inhibitory avoidance performance whilst NMDA receptor antagonists 3-(2-D-carboxypiperazin-4-yl)propyl-1-phosphoric acid (CPP) and MK-801 impaired it. Moreover we observed that the NMDA receptor antagonist-induced impairment of memory consolidation was attenuated by subeffective doses of SKF 38393 (5 mg/kg) and quinpirole (0.25 mg/kg). Impairment of the response induced by post-trial injections of CPP and MK-801, in the one-trial inhibitory avoidance test, was highly enhanced by 14 days of daily administration of haloperidol (4 mg/kg), sulpiride (25 mg/kg) but also SCH 23390 (0.5 mg/kg). These results suggest that different neural mechanisms underlie the functional interaction between the two neural systems in the modulation of these behavioral responses. Further, the results of the chronic study revealed a possible heterologous regulation of NMDA receptors.
运动活性和通过单次试验抑制性回避评估的记忆巩固。与先前的报道一致,NMDA受体拮抗剂(+)-MK-801((+)-5-甲基-10,11-二氢(a,d)环庚烯-5,10-亚胺马来酸氢盐)剂量依赖性地增强了小鼠的运动活性。选择性多巴胺D1受体拮抗剂SCH 23390在高达0.05mg/kg的剂量下无法影响MK-801诱导的运动活性,而(-)-舒必利,但仅在高剂量(30mg/kg)时,以及氟哌啶醇(0.05mg/kg)可阻断MK-801的作用。重复给予氟哌啶醇(4mg/kg,每日一次,共14天)或(-)-舒必利(125mg/kg)可增强MK-801诱导的运动亢进,但SCH 23390(0.5mg/kg)则无此作用。多巴胺D1(SKF 38393)和D2(喹吡罗)选择性激动剂可增强单次试验抑制性回避表现的保持,而NMDA受体拮抗剂3-(2-D-羧基哌嗪-4-基)丙基-1-磷酸(CPP)和MK-801则损害该表现。此外,我们观察到亚有效剂量的SKF 38393(5mg/kg)和喹吡罗(0.25mg/kg)可减轻NMDA受体拮抗剂诱导的记忆巩固损害。在单次试验抑制性回避试验中,试验后注射CPP和MK-801诱导的反应损害在每日给予氟哌啶醇(4mg/kg)、舒必利(25mg/kg)以及SCH 23390(0.5mg/kg)14天后显著增强。这些结果表明,在调节这些行为反应时,两种神经系统之间的功能相互作用存在不同的神经机制。此外,长期研究结果揭示了NMDA受体可能存在异源调节。